Neurocrine Biosciences (NBIX) Non Operating Income (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Non Operating Income for 17 consecutive years, with $10.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income fell 23.02% year-over-year to $10.7 million; the trailing twelve-month figure through Jun 2026 stood at $145.4 million (up 352.96% YoY), and the FY2025 full-year result was $86.3 million, up 202.13% from the prior year.
• Non Operating Income declined to $10.7 million in Q2 2026 per NBIX's latest filing, from $53.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $53.4 million in Q1 2026 and bottomed at -$78.0 million in Q2 2022.
• Historically, Non Operating Income has averaged $6.2 million across 5 years, with a median of $12.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income slumped 1371.7% in 2022, then surged 712.31% in 2025.
• Over 5 years, Non Operating Income stood at $14.5 million in 2022, then surged by 230.34% to $47.9 million in 2023, then slumped by 56.99% to $20.6 million in 2024, then surged by 38.35% to $28.5 million in 2025, then plunged by 62.46% to $10.7 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $10.7 million, $53.4 million, and $28.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.